Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease

Journal of Virology

Volumn 86, Issue 14, 2012, Pages 7544-7553

  Görander, Staffan ^a   Harandi, Ali M ^a   Lindqvist, Madelene ^a,b   Bergström, Tomas ^a   Liljeqvist, Jan Åke ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; THROMBOSPONDIN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DOSE RESPONSE; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; IN VITRO STUDY; LETHAL DOSE; MONOTHERAPY; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPINAL CORD; SURVIVAL RATE; UROGENITAL TRACT DISEASE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CERCOPITHECUS AETHIOPS; CPG ISLANDS; CRICETINAE; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; IMMUNIZATION; INTERFERON-GAMMA; MACROPHAGES; MICE; MICE, INBRED C57BL; NERVOUS SYSTEM DISEASES; SPINAL CORD; VAGINA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MUS;

EID: 84863741517     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00186-12     Document Type: Article

References (55)

1. Adamiak B, Ekblad M, Bergstrom T, Ferro V, Trybala E. 2007. Herpes simplex virus type 2 glycoprotein G is targeted by the sulfated oligo- and polysaccharide inhibitors of virus attachment to cells. J. Virol. 81:13424-13434.
2. Balachandran N, Bacchetti S, Rawls WE. 1982. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect. Immun. 37:1132-1137.
3. Balachandran N, Hutt-Fletcher LM. 1985. Synthesis and processing of glycoprotein gG of herpes simplex virus type 2. J. Virol. 54:825-832.
4. Balachandran N, Oba DE, Hutt-Fletcher LM. 1987. Antigenic crossreactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. J. Virol. 61:1125-1135.
5. Belshe RB, et al. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366:34-43.
6. Bergstrom T, Sjogren-Jansson E, Jeansson S, Lycke E. 1992. Mapping neuroinvasiveness of the herpes simplex virus type 1 encephalitisinducing strain 2762 by the use of monoclonal antibodies. Mol. Cell. Probes 6:41-49.
7. Bhat AA, Seth RK, Babu J, Biswas S, Rao DN. 2009. Induction of mucosal and systemic humoral immune responses in murine system by intranasal immunization with peptide antigens of P. vivax and CpG oligodeoxynucleotide (ODN) in microparticle delivery. Int. Immunopharmacol. 9:1197-1208.
8. Brown ZA, et al. 1997. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. 337:509-515.
9. Carmack MA, et al. 1996. T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and type 2. J. Infect. Dis. 174:899-906.
10. Chesler DA, Reiss CS. 2002. The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 13:441-454.
11. Chu CF, et al. 2008. Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and-independent mechanisms. J. Reprod. Immunol. 78:58-67.
12. Clavet CR, Margolin AB, Regan PM. 2004. Herpes simplex virus type-2 specific glycoprotein G-2 immunomagnetically captured from HEp-2 infected tissue culture extracts. J. Virol. Methods 119:121-128.
13. Cohen J. 2010. Immunology. Painful failure of promising genital herpes vaccine. Science 330:304.
14. Corey L, et al. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282:331-340.
15. Dalton DK, et al. 1993. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739-1742.
16. Dudley KL, Bourne N, Milligan GN. 2000. Immune protection against HSV-2 in B-cell-deficient mice. Virology 270:454-463.
17. Eriksson K, et al. 2004. CD4(+) T-cell responses to herpes simplex virus type 2 (HSV-2) glycoprotein G are type specific and differ in symptomatic and asymptomatic HSV-2-infected individuals. J. Gen. Virol. 85:2139-2147.
18. Fleming DT, et al. 1997 Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-1111.
19. Freeman EE, et al. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83.
20. Gallichan WS, et al. 2001. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166:3451-3457.
21. Grabowska AM, et al. 2000. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology 269:47-53.
22. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. 2001. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 82:845-853.
23. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. 2001. Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-gammadependent RANTES production following a vaginal viral challenge. Am. J. Reprod. Immunol. 46:420-424.
24. Iijima N, et al. 2008. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J. Exp. Med. 205:3041-3052.
25. Ishizaka ST, Piacente P, Silva J, Mishkin EM. 1995. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoproteinDmonoclonal antibodies. J. Infect. Dis. 172:1108-1111.
26. Jeansson S, Molin L. 1974. On the occurrence of genital herpes simplex virus infection. Clinical and virological findings and relation to gonorrhoea. Acta Derm. Venereol. 54:479-485.
27. Johnson AJ, Chu CF, Milligan GN. 2008. Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J. Virol. 82:9678-9688.
28. Johnston C, Koelle DM, Wald A. 2011. HSV-2: in pursuit of a vaccine. J. Clin. Invest. 121:4600-4609.
29. Koelle DM, Corey L. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113.
30. Kohl S, Cahall DL, Walters DL, Schaffner VE. 1979. Murine antibodydependent cellular cytotoxicity to herpes simplex virus-infected target cells. J. Immunol. 123:25-30.
31. Kohl S, et al. 2000. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J. Infect. Dis. 181:335-339.
32. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. 1999. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N. Engl. J. Med. 341:1432-1438.
33. Liljeqvist JA, Svennerholm B, Bergstrom T. 1999. Herpes simplex virus type 2 glycoprotein G-negative clinical isolates are generated by single frameshift mutations. J. Virol. 73:9796-9802.
34. Liljeqvist JA, et al. 1998. Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies. J. Gen. Virol. 79(Pt 5):1215-1224.
35. Looker KJ, Garnett GP, Schmid GP. 2008. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 86:805-812, A.
36. Marsden HS, Buckmaster A, Palfreyman JW, Hope RG, Minson AC. 1984. Characterization of the 92,000-dalton glycoprotein induced by herpes simplex virus type 2. J. Virol. 50:547-554.
37. McClung H, Seth P, Rawls WE. 1976. Relative concentrations in human sera of antibodies to cross-reacting and specific antigens of herpes simplex virus types 1 and 2. Am. J. Epidemiol. 104:192-201.
38. McDermott MR, Brais PL, Ploettsche GC, Evelegh MJ, Goldsmith CH. 1987. Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes. Arch. Virol. 93:51-68.
39. Milligan GN, Bernstein DI. 1997. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229:259-268.
40. Morrison LA, Zhu L, Thebeau LG. 2001. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J. Virol. 75:1195-1204.
41. Namvar L, Olofsson S, Bergstrom T, Lindh M. 2005. Detection and typing of herpes simplex virus (HSV) in mucocutaneous samples by Taq-Man PCR targeting a gB segment homologous for HSV types 1 and 2. J. Clin. Microbiol. 43:2058-2064.
42. Olofsson S, Jeansson S, Lycke E. 1981. Unusual lectin-binding properties of a herpes simplex virus type 1-specific glycoprotein. J. Virol. 38:564-570.
43. Para MF, Parish ML, Noble AG, Spear PG. 1985. Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions. J. Virol. 55:483-488.
44. Parr EL, Parr MB. 1999. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 98:639-645.
45. Parr EL, Parr MB. 1998. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J. Virol. 72:5137-5145.
46. Parr MB, Parr EL. 2000. Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice. Immunology 101:126-131.
47. Parr MB, Parr EL. 1998. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. J. Virol. 72:2677-2685.
48. Parr MB, Parr EL. 1999. The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Virology 258:282-294.
49. Parr MB, Parr EL. 2003. Vaginal immunity in the HSV-2 mouse model. Int. Rev. Immunol. 22:43-63.
50. Ravetch JV, Kinet JP. 1991. Fc receptors. Annu. Rev. Immunol. 9:457-492.
51. Roizman B, Norrild B, Chan C, Pereira L. 1984. Identification and preliminary mapping with monoclonal antibodies of a herpes simplex virus type 2 glycoprotein lacking a known type 1 counterpart. Virology 133:242-247.
52. Smith JS, Robinson NJ. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186(Suppl 1):S3-S28.
53. Stanberry LR, et al. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
54. Su HK, Courtney RJ. 1988. Inducible expression of herpes simplex virus type 2 glycoprotein gene gG-2 in a mammalian cell line. J. Virol. 62:3668-3674.
55. Svennerholm B, Olofsson S, Jeansson S, Vahlne A, Lycke E. 1984. Herpes simplex virus type-selective enzyme-linked immunosorbent assay with Helix pomatia lectin-purified antigens. J. Clin. Microbiol. 19:235-239.